Please use this identifier to cite or link to this item:
|Title:||Guidelines for treatment of osteoporosis in men|
|Citation:||Australian Family Physician, 2001; 30(8):787-791|
|Publisher:||Royal Australian College of General Practitioners|
|Abstract:||Background: Osteoporosis is associated with significant morbidity and mortality in men. Published randomised controlled trials assessing the benefits of therapy in men with osteoporosis are limited, but those available need to be used to develop management guidelines. Objective: To present evidence based guidelines for the treatment of osteoporosis in men. Discussion: It is estimated that 30-60% of men presenting with spinal fractures have another illness contributing to their bone disease. Therefore assessment and treatment of coexisting medical conditions is a vital part of management of osteoporosis. While primary prevention of fractures remains crucial, treatment to ensure further fractures do not occur is equally important. Alendronate is the treatment of choice for men with osteoporosis and fractures, with cyclical editronate an appropriate aternative and testosterone replacement therapy is indicated in hypogonadal men presenting with osteoporosis.|
|Keywords:||Humans; Osteoporosis; Calcium, Dietary; Diphosphonates; Testosterone; Calcitriol; Vitamin D; Male; Randomized Controlled Trials as Topic; Practice Guidelines as Topic|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.